Fosun Kite Celebrates Triple Recognition as a High-Caliber Enterprise in Shanghai

ShanghaiMarch 23, 2023PR Newswire -- Recently, the Shanghai Municipal Commission of Economy and Informatization officially released the 2022 list of "Specialized, Precise, Unique, and Innovative" enterprises in Shanghai. Fosun Kite Biotechnology Co., Ltd. successfully obtained the recognition as a "Specialized, Precise, Unique, and Innovative" enterprise based on its innovative achievements in high-quality development within the cell therapy field and leading competitive advantages in the market. This marks another authoritative certification from a government department for Fosun Kite, following its recognition as a Shanghai High-Tech Enterprise at the end of 2022 and as an Innovative Small and Medium-sized Enterprise in Shanghai in March 2023.

"Specialized,精细化, Specialized, and Innovative" enterprises specifically refer to companies with core traits of specialization, refinement, uniqueness, and innovation, forming the leading group in细分fields of the industry chain. The recognition as a "Specialized, Refined, Specialized, and Innovative" enterprise this time represents the high recognition from government departments of Fosun Kite's consistent embracement of change, adherence to innovative breakthroughs in technology philosophy, and its continuous efforts in pioneering innovations and setting industry benchmarks.

At the same timeHigh-tech enterprises, innovative small and medium-sized enterprises, and specialized and new enterprises all represent a comprehensive evaluation of a company's product development, technological innovation, achievement transformation, and organizational management. The consecutive receipt of these three honors not only demonstrates the full recognition by relevant Shanghai municipal government departments of Fosun Kite’s comprehensive strength but also signifies deep expectations and encouragement for the company’s future development prospects.

Since its establishment, Fosun Kite has been committed to the research and development of immunotherapy for lymphoma, and was the first to receive approval for marketing in June 2021.The First in ChinaCAR-T Cell Therapy Product - Yikai Da® (Axicabtagene Ciloleucel Injection) has successfully treated over 400 patients with relapsed/refractory large B-cell lymphoma. In October 2022, the supplemental application for a second-line indication for Yikai Da® submitted by Fosun Kite Biotechnology Co., Ltd. was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This means that adult patients with large B-cell lymphoma who are ineffective with first-line immunochemotherapy or relapse within 12 months after first-line immunochemotherapy will benefit.

As a leader in China's cell and gene therapy field, Fosun Kite is currently actively expanding more indications for Yikaida, developing new targets and technologies, and accelerating the R&D process in the solid tumor field. In the future, Fosun Kite will continue to forge ahead by adopting a "three-pronged approach" of technology transfer, independent research and development, and joint development. It will increase investment in innovative R&D, promote the transformation of innovative achievements, and use more cutting-edge technologies and higher-quality products to benefit more Chinese patients and lead the advancement of China's cell and gene therapy industry.